SCHEMBL2948843

SCHEMBL2948843

FC(F)(F)c1cccc(Nc2c(-c3ccccc3)nc3cnccn23)c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 10/20 0.78
MAPT P10636 7/20 0.78
KDM4E B2RXH2 4/20 0.62
BRAF P15056 3/20 0.62
LMNA P02545 3/20 0.62
MAPK1 P28482 2/20 0.62
SYK P43405 1/20 0.57
TP53 P04637 2/20 0.54
ALDH1A1 P00352 3/20 0.53
HSD17B10 Q99714 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
IDH2 P48735 1/20 0.53
HPGD P15428 1/20 0.52
ALOX15 P16050 1/20 0.52
CASP1 P29466 1/20 0.52
CASP7 P55210 1/20 0.52
FLT1 P17948 1/20 0.50
FLT4 P35916 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31193329 0.94 GAA (0.78) GAAMAPTKDM4EBRAFLMNA
SCHEMBL2919660 0.85 GAA (0.66) GAAMAPTKDM4EBRAFLMNA
SCHEMBL2923400 0.85 GAA (0.83) GAAMAPTKDM4EBRAFLMNA
SCHEMBL31355336 0.85 GAA (0.71) GAAMAPTKDM4ELMNAMAPK1
SCHEMBL31193347 0.83 GAA (0.65) GAAMAPTKDM4EBRAFLMNA
SCHEMBL2943722 0.83 GAA (0.66) GAAMAPTKDM4EBRAFLMNA
SCHEMBL2921992 0.83 GAA (0.77) GAAMAPTKDM4EBRAFLMNA
SCHEMBL2923964 0.83 BRAF (0.69) GAAMAPTKDM4EBRAFLMNA
SCHEMBL2921758 0.83 BRAF (0.77) GAAMAPTKDM4EBRAFLMNA
SCHEMBL14022519 0.82 GAA (0.77) GAAMAPTKDM4ELMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1901748-B1 ANGIOGENESIS INHIBITORS ONCALIS AG (CH) 2010-09-08 EP disclosed
EP-1901748-B1 ANGIOGENESIS INHIBITORS ONCALIS AG (CH) 2010-09-08 EP disclosed
EP-1765351-B9 PROTEIN KINASE INHIBITORS ONCALIS AG (CH) 2010-03-24 EP disclosed
EP-1765351-B1 PROTEIN KINASE INHIBITORS ONCALIS AG (CH) 2009-03-04 EP disclosed
US-20070149535-A1 Protein kinase inhibitors ONCALIS AG (CH) 2007-06-28 US disclosed
US-20070149535-A1 Protein kinase inhibitors ONCALIS AG (CH) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149535-A1 Protein kinase inhibitors FLT1, ERBB2, ERBB3 GAA 3677/4885MAPT 3858/4885KDM4E 1064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.